Navigation Links
Compendia Bioscience and H3 Biomedicine Announce Strategic Collaboration to Apply Cancer Genomics to Discover and Develop Next Generation Cancer Therapeutics
Date:2/14/2012

ANN ARBOR, Mich. and CAMBRIDGE, Mass., Feb. 14, 2012 /PRNewswire-USNewswire/ -- Compendia Bioscience today announced that it has signed a three-year licensing agreement with H3 Biomedicine, Inc. to Compendia's full suite of Oncomine tools including Oncomine Concepts Edition and Oncomine Power Tools Edition.

In addition, Compendia and H3 will work together to mine data from The Cancer Genome Atlas (TCGA) to discover novel therapeutic targets and biomarkers to support drug development.

 "We are really excited to welcome H3 Biomedicine as a new partner and customer," said Daniel Rhodes, Ph.D., Compendia's co-founder and CEO. "H3 has developed a unique and compelling business strategy that is perfectly aligned with Compendia's vision for cancer drug discovery and development. We could not be more pleased to be working with them to make their vision into a reality."

"Compendia is the clear and recognized industry leader in applying cancer genomics to the discovery and development of cancer therapeutics," said Dr. Markus Warmuth, the CEO of H3 Biomedicine. "As we aim to develop H3 into a potent cancer drug discovery enterprise, it is clear that we need to partner with companies such as Compendia that think about cancer in the same way we do, that believe the development of cancer therapeutics begins with a clear understanding of the molecular characteristics and diversity of cancer patients."

About Compendia Bioscience, Inc.

Compendia Bioscience is dedicated to curing cancers through the application of genomic data by providing researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes. Visit www.compendiabio.com for more information.

About Oncomine™

Oncomine combines a rapidly growing compendium of 62,000+ expertly curated cancer genomic profiles with a sophisticated analysis engine and powerful web applications for data mining and visualization. Oncomine facilitates target discovery and validation and supports the prioritization of tumor populations for drug development. Visit www.oncomine.com for more information.

About H3 Biomedicine Inc.

H3 Biomedicine is a biopharmaceutical company specializing in the discovery and development of oncology treatments. Using modern synthetic chemistry, chemical biology and human genetics, the company seeks to bring the next generation of cancer treatments to market with the goal of improving the lives of patients. H3 Biomedicine is based in Cambridge, Massachusetts. Visit www.H3biomedicine.com for more information.

About Eisai Inc.

Eisai Inc. was established in 1995 and began marketing its first product in the United States in 1997. Since that time, Eisai Inc. has rapidly grown to become a fully integrated pharmaceutical business. Eisai's key areas of commercial focus are neurology and oncology. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as manufacturing facilities in Maryland and North Carolina. The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com/US.


'/>"/>
SOURCE Compendia Bioscience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AAIPharma Services Announces 24/7 Online Compendial Raw Materials Testing
2. AAIPharma Services Announces Compendial Testing Facility Expansion
3. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
4. PuraMed BioScience, Inc. Announces LipiGesic®M, Their Unique Migraine Treatment, is Now Available for Purchase at CVS, the 2nd Largest Drug Chain in the United States
5. INVO Bioscience Announces Approval of INVOcell by Brazils ANVISA
6. Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock
7. Neurocrine Biosciences, Inc. Announces Proposed Public Offering of Common Stock
8. Roka Bioscience Awarded AOAC-RI Certification for Roka Listeria Detection Assay
9. Ambit Biosciences to Present at 30th Annual J.P. Morgan Healthcare Conference
10. Neurocrine Biosciences to Present at the 30th Annual J.P. Morgan Healthcare Conference
11. Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Medical, Inc. (Nasdaq: AEMD ), the pioneer ... diseases, today announced results for the third quarter ... --> --> "Beyond ... quarterly call, we strategically advanced pre-clinical and clinical ... the Aethlon Hemopurifier® as a leading broad-spectrum countermeasure ...
(Date:2/4/2016)... N.Y. , Feb. 4, 2016  AMRI (NASDAQ:  AMRI) ... President of Pfizer Inc. and President of Pfizer Global Supply, ... as of February 4, 2016. In addition, the Company announced ... of the audit committee since 2010, has retired from the ... and attention to his other business ventures.  ...
(Date:2/4/2016)... PUNE, India , February 4, 2016 ... to the new Market Research Report "North American Automated ... and Fully-Automated External Defibrillators), by End-User (Public Facilities, Hospitals, ... North American automated external defibrillators (AED) report defines and ... of the revenue. This market is estimated to grow ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... February 06, 2016 , ... ... MEDIA ADVISORY: 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO ... in the world with an estimated 5000 perioperative nurses in attendance to ...
(Date:2/5/2016)... ... February 05, 2016 , ... Steven Tonkinson, 36, of ... completed every year since it started in 2003. This year, he ran all 26.2 ... fellow runners and NBA team the Miami Heat. , This Sunday, while many are ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... ... February 05, 2016 , ... After years as an active staff surgeon ... and cosmetic surgeon Dr. Wayne Carman transitioned to chief of the Division of Plastic ... first three-year term as chief and began a second three-year term in January of ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... gym use and find themselves having to wait longer to access the treadmills. It’s ... their New Year’s resolutions to lose weight and get in shape by joining gyms, ...
Breaking Medicine News(10 mins):